Common Contracts
2 similar Equity Underwriting Agreement contracts by Marchex Inc, Vascular Biogenics Ltd.
Ÿ] Ordinary Shares Vascular Biogenics Ltd. Ordinary Shares (NIS 0.01 Nominal Value) EQUITY UNDERWRITING AGREEMENTEquity Underwriting Agreement • September 30th, 2014 • Vascular Biogenics Ltd. • Pharmaceutical preparations • New York
Vascular Biogenics Ltd., an Israeli company (the “Company”), proposes to sell to the several underwriters (the “Underwriters”) named on Schedule I hereto for whom you are acting as the representative (the “Representative”) an aggregate of [•] shares (the “Firm Shares”) of the Company’s ordinary shares, NIS 0.01 nominal value (the “Ordinary Shares”). The respective amounts of the Firm Shares to be so purchased by the several Underwriters are set forth opposite their names on Schedule I hereto. The Company also proposes to sell at the Underwriters’ option an aggregate of up to [•] additional shares of the Company’s Ordinary Shares (the “Option Shares”) as set forth below.
5,714,000 Shares MARCHEX, INC. Class B Common Stock ($0.01 Par Value) EQUITY UNDERWRITING AGREEMENTEquity Underwriting Agreement • April 1st, 2014 • Marchex Inc • Services-business services, nec • New York
Marchex, Inc., a Delaware corporation (the “Company”), and certain shareholders of the Company (the “Selling Shareholders”) propose to sell to the several underwriters (the “Underwriters”) named on Schedule I hereto for whom you are acting as representative (the “Representative”) an aggregate of 5,714,000 shares (the “Firm Shares”) of the Company’s Class B Common Stock, $0.01 par value (the “Common Stock”), of which 2,857,000 shares will be sold by the Company and 2,857,000 shares will be sold by the Selling Shareholders. The respective amounts of the Firm Shares to be so purchased by the several Underwriters are set forth opposite their names on Schedule I hereto, and the respective amounts to be sold by the Selling Shareholders are set forth opposite their names on Schedule II hereto. The Company and the Selling Shareholders are sometimes referred to herein collectively as the “Sellers”. The Company and the Selling Shareholders also propose to sell at the Underwriters’ option an aggr
